A combination of STI571 and BCR-ABL1 siRNA with overexpressed p15INK4B induced enhanced proliferation inhibition and apoptosis in chronic myeloid leukemia

被引:6
|
作者
Xia, D. Y. [1 ]
Liu, L. [1 ]
Hao, M. W. [1 ]
Liu, Q. [1 ]
Chen, R. A. [1 ]
Liang, Y. M. [1 ]
机构
[1] Fourth Mil Med Univ, Tangdu Hosp, Dept Hematol, Xian 710038, Peoples R China
关键词
Apoptosis; Chronic myeloid leukemia; p15INK4B; STI571; (Gleevec; imatinib); CHRONIC MYELOGENOUS LEUKEMIA; IMATINIB RESISTANCE; CELLS; P16(INK4A); MUTATIONS; PATHWAY; PATIENT;
D O I
10.1590/1414-431X20143734
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
p15INK4B, a cyclin-dependent kinase inhibitor, has been recognized as a tumor suppressor. Loss of or methylation of the p15INK4B gene in chronic myeloid leukemia (CML) cells enhances myeloid progenitor formation from common myeloid progenitors. Therefore, we examined the effects of overexpressed p15INK4B on proliferation and apoptosis of CML cells. Overexpression of p15INK4B inhibited the growth of K562 cells by downregulation of cyclin-dependent kinase 4 (CDK4) and cyclin D1 expression. Overexpression of p15INK4B also induced apoptosis of K562 cells by upregulating Bax expression and downregulating Bcl-2 expression. Overexpression of p15INK4B together with STI571 (imatinib) or BCR-ABL1 small interfering RNA (siRNA) also enhanced growth inhibition and apoptosis induction of K562 cells. The enhanced effect was also mediated by reduction of cyclin D1 and CDK4 and regulation of Bax and Bcl-2. In conclusion, our study may provide new insights into the role of p15INK4B in CML and a potential therapeutic target for overcoming tyrosine kinase inhibitor resistance in CML.
引用
收藏
页码:1096 / 1101
页数:6
相关论文
共 24 条
  • [1] Study on the treatment of the p15 gene combined with Bcr-abl-specific siRNA and STI571 for chronic myeloid leukemia
    Wang, W.
    Du, Y.
    Li, N. -N.
    Lv, F. -F.
    Lin, G. -Q.
    GENETICS AND MOLECULAR RESEARCH, 2014, 13 (02) : 4089 - 4101
  • [2] STI571 administered to chronic myeloid leukemia (CML) patients inhibits cell proliferation, induces apoptosis and initially causes partial inhibition of BCR/ABL autophosphorylation.
    Gambacorti-Passerini, C
    Verga, M
    Rossi, F
    Tornaghi, L
    Bungaro, S
    Ruchatz, H
    Rossi, F
    Pioltelli, P
    Pogliani, E
    Garattini, E
    Capdeville, R
    D'Incalci, M
    Corneo, G
    BLOOD, 2000, 96 (11) : 345A - 345A
  • [3] Inhibition of isoprenylcysteine carboxylmethyltransferase augments BCR-ABL1 tyrosine kinase inhibition-induced apoptosis in chronic myeloid leukemia
    Sun, Wen Tian
    Xiang, Wei
    Ng, Bee Ling
    Asari, Kartini
    Bunte, Ralph M.
    Casey, Patrick J.
    Wang, Mei
    Chuah, Charles
    EXPERIMENTAL HEMATOLOGY, 2016, 44 (03) : 189 - 193
  • [4] Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571
    Koyama, N
    Koschmieder, S
    Tyagi, S
    Portero-Robles, I
    Chromic, J
    Myloch, S
    Nurnberger, H
    Rossmanith, T
    Hofmann, WK
    Hoelzer, D
    Ottmann, OG
    CLINICAL CANCER RESEARCH, 2006, 12 (07) : 2025 - 2031
  • [5] Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair
    Majsterek, I
    Sliwinski, T
    Poplawski, T
    Pytel, D
    Kowalski, M
    Slupianek, A
    Skorski, T
    Blasiak, J
    MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS, 2006, 603 (01) : 74 - 82
  • [6] In vitro treatment of chronic myeloid leukemia cells with STI571 leads to an equal reduction of Wilms tumor gene (WT1) and bcr/abl mRNA transcripts.
    Kreuzer, KA
    Coutre, PI
    Saborowski, A
    Lupberger, J
    Appelt, C
    Na, IK
    Bohn, A
    Schmidt, CA
    BLOOD, 2000, 96 (11) : 98A - 99A
  • [7] Roles of p15Ink4b and p16Ink4a in myeloid differentiation and RUNX1-ETO-associated acute myeloid leukemia
    Ko, Rose M.
    Kim, Hyung-Gyoon
    Wolff, Linda
    Klug, Christopher A.
    LEUKEMIA RESEARCH, 2008, 32 (07) : 1101 - 1111
  • [8] P53, p15INK4B, p16INK4A and p57KIP2 mutations during the progression of chronic myeloid leukemia
    Güran, S
    Bahçe, M
    Beyan, C
    Korkmaz, K
    Yalçin, A
    HAEMATOLOGIA, 1998, 29 (03) : 181 - 193
  • [9] p19INK4d inhibits proliferation and enhances imatinib efficacy through BCR-ABL signaling pathway in chronic myeloid leukemia
    Kuang, Yijin
    Han, Xu
    Cao, Pengfei
    Xiong, Dehui
    Peng, Yuanliang
    Liu, Zhaoping
    Xu, Zhenru
    Liang, Long
    Roy, Mridul
    Liu, Jing
    Nie, Ling
    Zhang, Ji
    BLOOD CELLS MOLECULES AND DISEASES, 2020, 85
  • [10] Strategies to re-express epigenetically silenced p15INK4b and p21WAF1 genes in acute myeloid leukemia
    Geyer, C. Ronald
    EPIGENETICS, 2010, 5 (08) : 696 - 703